A method for detecting genotoxic impurities in betahistine mesylate
Detection of methanesulfonic acid-2-pyridine ethanol ester in betastine methanesulfonic acid by combining high-performance liquid chromatography and mass spectrometry, solving the problem that the existing technology cannot effectively detect this impurity, and achieving high sensitivity and high precision Testing ensures the quality of drugs and the safety of medication.
Patent Information
- Application Number
- CN202311266425.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-27
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-09-27
AI Technical Summary
The prior art cannot effectively detect the genotoxic impurity methanesulfonate-2-pyridine ethanol ester in betastine methanesulfonate, making it difficult to meet drug quality monitoring and drug safety requirements.
Using high performance liquid chromatography and mass spectrometry, the trace amount of methanesulfonic acid-2-pyridine in raw materials or preparations is achieved through C18 chromatography column and specific mobile phase gradient elution method, combined with mass spectrometry conditions. Accurate detection of ethanol ester.
The accurate detection of trace amounts of methanesulfonate-2-pyridine ethanol ester in betastine methanesulfonate was achieved, with a detection limit of 1.99ng/mg and a quantitative limit of 3.98ng/mg, which meets the detection requirements of ICH M7. It improves the sensitivity and precision of the detection, ensuring the quality of the drug and the safety of the drug.
Smart Images

Figure CN117310034B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of drug analysis, and in particular to a method for detecting genotoxic impurities in betahistine mesylate. Background Art
[0002] Betahistine mesylate, English name is N-Methyl-2-pyridineethylamine dimethanesulphonate, chemical name is N-methyl-2-pyridineethylamine dimethanesulfonate, the structural formula is as follows. Betahistine mesylate is a vasodilator, used to treat inner ear vertigo (i.e. Meniere's syndrome), cerebral arteriosclerosis, cerebral insufficiency, as well as dizziness, vomiting and tinnitus caused by hypertension.
[0003]
[0004] The existing process for synthesizing betahistine mesylate may cause the process intermediate 2-ethanol pyridine to react with the raw material methanesulfonic acid to generate the genotoxic impurity methanesulfonic acid-2-pyridine ethanol ester (CAS No. 138428-37-2), the structural formula of which is as follows. According to the ICH M7 guidelines, the acceptable limit of methanesulfonic acid-2-pyridine ethanol ester in betahistine mesylate = TTC (μg / day) × 1000 / MDD (mg / day) = = 1.5μg / day × 1000 / 36mg / day = 41.67ppm (ng / mg); where TTC represents the threshold of toxicological concern and MDD represents the maximum daily dose. It is strictly controlled at 40ppm, that is, it shall not exceed 0.004%.
[0005]
[0006] At present, there is no relevant report on the detection method of 2-pyridine ethanol mesylate, and the sensitivity of conventional high performance liquid chromatography and gas chromatography detection methods cannot meet the detection requirements of 2-pyridine ethanol mesylate in betahistine mesylate. In order to better monitor the quality of betahistine mesylate raw materials or its preparations and ensure the clinical drug safety of betahistine mesylate products, it is necessary to develop a method for accurately and reliably detecting 2-pyridine ethanol mesylate in betahistine mesylate raw materials or its preparations. Summary of the invention
[0007] Aiming at the problem that the prior art cannot effectively detect 2-pyridineethanol mesylate in betahistine mesylate raw materials or preparations, the present invention provides a method for detecting genotoxic impurities in betahistine mesylate.
[0008] In order to solve the above technical problems, the technical solution provided by the present invention is:
[0009] A method for detecting genotoxic impurities in betahistine mesylate, wherein the genotoxic impurity is 2-pyridineethanol mesylate, and high performance liquid chromatography-mass spectrometry is used for detection, comprising the following steps:
[0010] (1) Preparation of test solution and reference solution:
[0011] Take betahistine mesylate raw material or its preparation, and prepare the test solution with water;
[0012] Take 2-pyridiniumethanol methanesulfonate reference substance and prepare reference substance solution with water;
[0013] (2) Testing the reference solution and the test solution, wherein the conditions of the high performance liquid chromatography are:
[0014] A C18 chromatographic column was used, with a 0.05%-0.2% formic acid aqueous solution as the mobile phase A, and a 0.05%-0.2% formic acid methanol solution as the mobile phase B, and gradient elution was performed;
[0015] The mass spectrometer adopts ESI ion source and positive ion detection mode, wherein the quantitative ion of the methanesulfonic acid-2-pyridineethanol ester is: the parent ion is 202.3m / z, the daughter ion is 106.2m / z, and the collision voltage is 25V.
[0016] The inventors found in the preparation process of betahistine mesylate API that the process intermediate 2-ethanol pyridine reacts with the raw material methanesulfonic acid to generate a process impurity containing a sulfonate, a genotoxic warning structure, i.e., 2-pyridine ethanol mesylate. In order to improve the safety of betahistine mesylate API or its preparation and reduce the risk of medication, the content of 2-pyridine ethanol mesylate should be detected and controlled according to genotoxic impurities. However, there is currently no report on the detection of 2-pyridine ethanol mesylate.
[0017] Relative to the prior art, the detection method of genotoxic impurities in betahistine mesylate provided by the present invention adopts a C18 chromatographic column, through a specific mobile phase, in a gradient elution mode, in conjunction with specific mass spectrometry conditions, to achieve accurate detection of trace amounts of methanesulfonic acid-2-pyridineethanol ester in betahistine mesylate raw materials or preparations thereof, and the detection limit of methanesulfonic acid-2-pyridineethanol ester is 1.99ng / mg, and the quantitative limit is 3.98ng / mg, which meets the detection requirements of the guiding principles of ICH M7. And the method provided by the present invention has strong specificity, high sensitivity, good linear relationship, and good precision and durability. It can achieve trace detection of potential process impurities methanesulfonic acid-2-pyridineethanol ester in betahistine mesylate raw materials or preparations thereof, and can be used as the basis for quality monitoring of betahistine mesylate drugs, making up for the blank that the prior art cannot effectively detect methanesulfonic acid-2-pyridineethanol ester in betahistine mesylate, and thus is conducive to reducing the drug safety risk of betahistine mesylate drugs.
[0018] Preferably, mobile phase A is a formic acid aqueous solution with a volume concentration of 0.1%, and mobile phase B is a formic acid methanol solution with a volume concentration of 0.1%.
[0019] The preferred mobile phase can better separate betahistine mesylate and 2-pyridineethanol mesylate without generating baseline interference, and can effectively improve the peak shape, thereby making the detection result more accurate and precise.
[0020] Preferably, the elution procedure of the gradient elution is as follows:
[0021] 0 min, 87%-83% mobile phase A, 13%-17% mobile phase B;
[0022] 3 min, 87%-83% mobile phase A, 13%-17% mobile phase B;
[0023] 5 min, 72%-68% mobile phase A, 28%-32% mobile phase B;
[0024] 9 min, 7%-3% mobile phase A, 93%-97% mobile phase B;
[0025] 10 min, 7%-3% mobile phase A, 93%-97% mobile phase B;
[0026] 10.1 min, 87%-83% mobile phase A, 13%-17% mobile phase B;
[0027] 15 min, 87%-83% mobile phase A, 13%-17% mobile phase B.
[0028] Further preferably, the elution procedure of the gradient elution is as follows:
[0029] 0 min, 85% mobile phase A, 15% mobile phase B;
[0030] 3 min, 85% mobile phase A, 15% mobile phase B;
[0031] 5 min, 70% mobile phase A, 30% mobile phase B;
[0032] 9 min, 5% mobile phase A, 95% mobile phase B;
[0033] 10 min, 5% mobile phase A, 95% mobile phase B;
[0034] 10.1 min, 85% mobile phase A, 15% mobile phase B;
[0035] 15 min, 85% mobile phase A, 15% mobile phase B.
[0036] The preferred gradient elution sequence can improve the separation degree between the main component and 2-pyridineethanol methanesulfonate and the detection sensitivity, so that the detection result is quantitatively accurate and has high precision.
[0037] Preferably, the scanning mode of the mass spectrometer is multiple reaction monitoring, the curtain gas pressure is 40psi, the collision gas is Medium, the declustering voltage is 100V, the injection voltage is 5V-15V, the collision chamber emission voltage is 5V-15V, the ionization voltage is 5500V-4500V, the spray gas pressure is 50psi-60psi, the auxiliary heating gas pressure is 50psi-60psi, and the ionization temperature is 500℃-600℃.
[0038] Furthermore, the injection voltage was 10 V, the collision cell ejection voltage was 10 V, the ionization voltage was 5500 V, the spray gas pressure was 55 psi, the auxiliary heating gas pressure was 55 psi, and the ionization temperature was 550°C.
[0039] The optimal mass spectrometry detection conditions can maximize the accuracy of determining trace amounts of 2-pyridineethanol mesylate in betahistine mesylate.
[0040] Preferably, the chromatographic column is YMC-Triart C18, 4.6mm*100mm, 3μm.
[0041] The preferred chromatographic column can reduce baseline interference and improve the sensitivity and accuracy of methanesulfonic acid-2-pyridineethanol ester detection.
[0042] Preferably, the column temperature is 27°C-33°C, and the flow rate is 0.55 mL / min-0.65 mL / min.
[0043] More preferably, the column temperature is 30° C. and the flow rate is 0.6 mL / min.
[0044] Preferably, the injection volume is 1 μL.
[0045] The preferred detection conditions are conducive to the effective detection of 2-pyridineethanol mesylate in betahistine mesylate and improve the detection sensitivity, thereby achieving the purpose of effectively and accurately detecting the trace amount of 2-pyridineethanol mesylate in betahistine mesylate.
[0046] Preferably, the concentration of the test solution is 1 mg / mL.
[0047] The preferred test sample concentration is conducive to making the peak shape of the main component and the methanesulfonic acid-2-pyridineethanol ester impurity better, the column efficiency is high, and the integration is more accurate, which is conducive to more accurate calculation of the content of methanesulfonic acid-2-pyridineethanol ester in the test sample.
[0048] Preferably, the concentration of 2-pyridineethanol methanesulfonate in the reference solution is 40 ng / mL.
[0049] The detection method provided by the present invention can realize accurate quantitative detection of trace amounts of 2-pyridineethanol mesylate impurities in betahistine mesylate raw materials or preparations, thereby being beneficial to monitoring the synthesis process of betahistine mesylate, and being more beneficial to truly reflecting the quality of synthesized betahistine mesylate, thereby ensuring the clinical drug safety of betahistine mesylate products, and having high practical value. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 The chromatogram of the blank solution under 2.1 in Example 2;
[0051] Figure 2 The chromatogram of the reference solution under 2.1 in Example 2;
[0052] Figure 3 The chromatogram of the test solution under 2.1 in Example 2;
[0053] Figure 4 The chromatogram of the test sample plus reference solution under 2.1 in Example 2;
[0054] Figure 5 It is the chromatogram of the reference substance solution in Comparative Example 1. DETAILED DESCRIPTION
[0055] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0056] Example 1
[0057] 1.1 Solution preparation
[0058] (1) Blank solution: pure water.
[0059] (2) Reference substance stock solution: Take an appropriate amount of 2-pyridiniumethanol methanesulfonate reference substance, weigh it accurately, and dilute it with water to make a solution containing about 800 ng of 2-pyridiniumethanol methanesulfonate per 1 mL, which is used as the reference substance stock solution.
[0060] (3) Reference solution: Take 0.5 mL of the reference stock solution and place it in a 10 mL volumetric flask as the reference solution.
[0061] (4) Test solution: Take about 10 mg of betahistine mesylate, accurately weigh it, place it in a 10 mL volumetric flask, add water to dissolve and dilute to the scale, shake well and filter to prepare the test solution.
[0062] (5) Test sample plus reference solution: Take about 10 mg of betahistine mesylate test sample, accurately weigh it, put it into a 10-mL volumetric flask, add 0.5 mL of the above-mentioned reference stock solution, add water to dilute to the scale, shake well and filter. This is the test sample plus reference solution.
[0063] 1.2 Detection method of 2-pyridineethanol mesylate in betahistine mesylate raw materials or preparations:
[0064] Chromatographic column: YMC-Triart C18, 4.6mm*100mm, 3μm;
[0065] Mobile phase A: 0.1% formic acid in water;
[0066] Mobile phase B: 0.1% formic acid in methanol;
[0067] Flow rate: 0.6 mL / min;
[0068] Injection volume: 1 μL;
[0069] Column temperature: 30°C;
[0070] Gradient elution, the elution program is as follows:
[0071] min A phase% Phase B % 0 85 15 3 85 15 5 70 30 9 5 95 10 5 95 10.1 85 15 15 85 15
[0072] Mass spectrometry conditions: ESI ion source, positive ion detection mode, multiple reaction monitoring (MRM) scanning mode, curtain gas (CUR) pressure of 40 psi, collision gas (CAD) of Medium, declustering voltage (DP) of 100 V, injection voltage (EP) of 10 V, collision chamber ejection voltage (CXP) of 10 V, ionization voltage (IS) of 5500 V, spray gas pressure (GS1) of 55 psi, auxiliary heating gas pressure (GS2) of 55 psi, ionization temperature (TEM) of 550 °C, detection ion pairs and collision voltage (CE) are shown in the table below.
[0073]
[0074] Example 2
[0075] Methodological validation:
[0076] 2.1 Exclusivity
[0077] Take 1 μL of each of the blank solution (pure water), reference solution, test solution and test plus reference solution prepared in Example 1, and perform HPLC-MS / MS detection according to the above conditions, and record the chromatograms. Figure 1-Figure 4 shown.
[0078] The test results showed that the baseline was stable, and the blank solution and betahistine mesylate test sample had no interference with the detection of 2-pyridineethanol mesylate, indicating that this method has good specificity.
[0079] 2.2 Limit of detection and limit of quantification
[0080] Detection limit: Take the reference solution prepared in Example 1, dilute it quantitatively step by step with water, perform HPLC-MS / MS detection, record the chromatogram, and obtain the detection limit at a signal-to-noise ratio of not less than 3:1. The results are shown in Table 1.
[0081] Limit of quantitation: The reference solution prepared in Example 1 was diluted step by step with water, and HPLC-MS / MS was performed. The chromatogram was recorded, and the limit of quantitation was obtained at a signal-to-noise ratio of not less than 10:1. The results are shown in Table 1. Six portions of the limit of quantitation solution were prepared in parallel, and HPLC-MS / MS was performed. The chromatogram was recorded, and the precision of the limit of quantitation was observed. The results are shown in Table 2.
[0082] Table 1 Detection limit and quantification limit test results
[0083]
[0084]
[0085] Table 2 Quantitation limit repeatability test results
[0086]
[0087] The results show that the detection limit concentration of the method of the present invention for 2-pyridine ethanol methanesulfonate is 1.99 ng / mL, which is equivalent to 1.99 ng / mg of the main component being detected. The quantitative limit concentration of 2-pyridine ethanol methanesulfonate is 3.98 ng / mL, which is equivalent to 3.98 ng / mg of the main component being quantitatively detected, and the 6-shot quantitative limit repeatability is good. This proves that the method has high sensitivity and meets the detection requirements of impurities in finished products.
[0088] 2.3 Linear range
[0089] Take an appropriate amount of methanesulfonic acid 2-pyridineethanol ester reference substance, weigh it accurately, and use water to make solutions containing approximately 3.98 ng, 7.97 ng, 23.90 ng, 39.83 ng, 55.76 ng, and 79.66 ng of methanesulfonic acid 2-pyridineethanol ester per 1 mL as linear solutions.
[0090] Each linear solution was taken for HPLC-MS / MS detection and the spectrum was recorded. The concentration of 2-pyridineethanol methanesulfonate (ng / mL) was used as the abscissa and the peak area was used as the ordinate to draw a standard curve and calculate the regression equation. The results are shown in Table 3.
[0091] Table 3 Linearity test results of methanesulfonic acid-2-pyridine ethanol ester
[0092]
[0093] The test results showed that methanesulfonic acid 2-pyridineethanol ester had a good linear relationship in the concentration range of 3.98-79.66 ng / mL, the linear equation was y=385.87x-88.557, and the linear correlation coefficient was r=0.9998.
[0094] 2.4 Accuracy
[0095] Reference substance stock solution: Take an appropriate amount of 2-pyridineethanol methanesulfonate reference substance, accurately weigh it, and dilute it with water to make a solution containing approximately 800 ng of 2-pyridineethanol methanesulfonate per 1 mL, which is used as the reference substance stock solution.
[0096] 60% limit recovery solution: Take about 10 mg of betahistine mesylate test sample, accurately weigh it, place it in a 10 mL volumetric flask, add 0.3 mL of reference stock solution, add water to dissolve and dilute to the scale as the low recovery solution, and prepare three times in parallel.
[0097] 100% limit recovery solution: Take about 10 mg of betahistine mesylate test sample, accurately weigh it, place it in a 10 mL volumetric flask, add 0.5 mL of reference stock solution, add water to dissolve and dilute to the scale, as the medium recovery solution, prepare three times in parallel.
[0098] 140% limit recovery solution: Take about 10 mg of betahistine mesylate test sample, accurately weigh it, place it in a 10 mL volumetric flask, add 0.7 mL of reference stock solution, add water to dissolve and dilute to the scale as a high recovery solution, and prepare three copies in parallel.
[0099] The reference solution and each recovery solution were taken for HPLC-MS / MS detection, and the spectra were recorded. The recovery results are shown in Table 4.
[0100] Recovery rate (%) = (measured amount - original amount) / added amount × 100%.
[0101] Table 4 Methanesulfonic acid-2-pyridine ethanol ester recovery test results
[0102]
[0103]
[0104] The results showed that the recovery rate of 2-pyridineethanol methanesulfonate was between 94.81% and 100.34% within the limit concentration range of 60%-140%, and the method had good accuracy.
[0105] 2.5 Repeatability
[0106] Test solution: Take about 10 mg of betahistine mesylate test sample, accurately weigh it, put it in a 10 mL volumetric flask, add water to dissolve and dilute to the scale, shake well and filter, as the test solution, prepare 6 copies in parallel.
[0107] The prepared test solution was subjected to HPLC-MS / MS detection, and the chromatogram was recorded. The test results are shown in Table 5.
[0108] Table 5 Repeatability test results of 2-pyridineethanol methanesulfonate
[0109]
[0110] The test results showed that 6 solutions were prepared from the same batch of samples, and no 2-pyridiniumethanol methanesulfonate was detected in the test samples, indicating good reproducibility.
[0111] 2.6 Precision
[0112] Reference substance stock solution: Take an appropriate amount of 2-pyridineethanol methanesulfonate reference substance, accurately weigh it, and dilute it with water to make a solution containing approximately 800 ng of 2-pyridineethanol methanesulfonate per 1 mL, which is used as the reference substance stock solution.
[0113] Reference solution: Take 0.5 mL of reference stock solution and place it in a 10 mL volumetric flask as the reference solution.
[0114] The reference solution was taken for HPLC-MS / MS detection, and the sample was injected and tested 6 times continuously. The spectrum was recorded. The test results are shown in Table 6.
[0115] Table 6 Precision test results
[0116]
[0117] The results showed that after 6 consecutive tests, the peak area RSD of 2-pyridineethanol methanesulfonate was 1.77%, and the precision of this method was good.
[0118] 2.7 Durability
[0119] Reference substance stock solution: Take an appropriate amount of 2-pyridineethanol methanesulfonate reference substance, accurately weigh it, and dilute it with water to make a solution containing approximately 800 ng of 2-pyridineethanol methanesulfonate per 1 mL, which is used as the reference substance stock solution.
[0120] Reference solution: Take 0.5 mL of reference stock solution and place it in a 10 mL volumetric flask as the reference solution.
[0121] The reference solution was subjected to HPLC-MS / MS detection and the chromatogram was recorded. The durability of methanesulfonic acid-2-pyridineethanol ester was investigated by fine-tuning the chromatographic conditions: flow rate 0.65 mL / min and 0.55 mL / min, column temperature 33°C and 27°C, and mobile phase B in the gradient was adjusted by ±2%. The results are shown in Table 7.
[0122] Table 7 Durability test results of 2-pyridineethanol methanesulfonate
[0123]
[0124] The results showed that fine-tuning the chromatographic conditions had no effect on the detection of 2-pyridiniumethanol methanesulfonate, and the method had good durability.
[0125] 2.8 Intermediate precision
[0126] Test solution: Take about 10 mg of betahistine mesylate test sample, accurately weigh it, put it in a 10 mL volumetric flask, add water to dissolve and dilute to the scale, shake well and filter, as the test solution, prepare 6 copies in parallel.
[0127] Take the test solution prepared above and perform HPLC-MS / MS detection, and record the chromatogram. The date and operator of this part of the test are different from those of the repeatability test, and the test results are shown in Table 8.
[0128] Table 8 Intermediate precision test results
[0129]
[0130] The results showed that no 2-pyridinylethanol methanesulfonate was detected in any of the six test solutions, which was consistent with the repeatability results. The intermediate precision of this method was good.
[0131] 2.9 Stability
[0132] Reference substance stock solution: Take an appropriate amount of 2-pyridineethanol methanesulfonate reference substance, accurately weigh it, and dilute it with water to make a solution containing approximately 800 ng of 2-pyridineethanol methanesulfonate per 1 mL, which is used as the reference substance stock solution.
[0133] Reference solution: Take 0.5 mL of reference stock solution and place it in a 10 mL volumetric flask as the reference solution.
[0134] Test solution: Take about 10 mg of betahistine mesylate test sample, accurately weigh it, put it in a 10 mL volumetric flask, add water to dissolve and dilute to the scale, shake well and filter it as the test solution.
[0135] The reference solution and the test solution were placed at room temperature, and HPLC-MS / MS detection was performed every 0 h, 2 h, 4 h, 6 h, and 8 h, and the chromatograms were recorded. The test results are shown in Tables 9 and 10.
[0136] Table 9 Results of stability test of reference solution
[0137]
[0138] Table 10 Test solution stability test results
[0139]
[0140] The results showed that after the test solution was left at room temperature for 8 hours, no 2-pyridineethanol methanesulfonate was detected; after the reference solution was left at room temperature for 8 hours, the RSD of the peak area was 1.93%, demonstrating that the above solutions had good stability.
[0141] Comparative Example 1
[0142] The detection method of 2-pyridineethanol mesylate in betahistine mesylate raw material provided in this comparative example is exactly the same as that in Example 1, except that the mobile phase A is replaced with 5 mmol / L ammonium acetate aqueous solution. The reference solution prepared in Example 1 is sampled and tested. The results are as follows: Figure 5 shown.
[0143] It can be seen from the figure that the response intensity of 2-pyridineethanol methanesulfonate in the reference solution is significantly reduced, and accurate quantitative calculation of 2-pyridineethanol methanesulfonate cannot be achieved.
[0144] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for detecting genotoxic impurities in betahistine mesylate, characterized in that: The genotoxic impurity is 2-pyridineethanol methanesulfonate, which is detected by high performance liquid chromatography-mass spectrometry, comprising the following steps: (1) Preparation of test solution and reference solution: Take betahistine mesylate raw material or its preparation, and prepare the test solution with water; Take 2-pyridiniumethanol methanesulfonate reference substance and prepare reference substance solution with water; (2) Testing the reference solution and the test solution, wherein the conditions of the high performance liquid chromatography are: A C18 chromatographic column was used, with a 0.05%-0.2% formic acid aqueous solution as mobile phase A, and a 0.05%-0.2% formic acid methanol solution as mobile phase B, and gradient elution was performed; The elution procedure of the gradient elution is as follows: 0 min, 87%-83% mobile phase A, 13%-17% mobile phase B; 3 min, 87%-83% mobile phase A, 13%-17% mobile phase B; 5 min, 72%-68% mobile phase A, 28%-32% mobile phase B; 9 min, 7%-3% mobile phase A, 93%-97% mobile phase B; 10 min, 7%-3% mobile phase A, 93%-97% mobile phase B; 10.1 min, 87%-83% mobile phase A, 13%-17% mobile phase B; 15 min, 87%-83% mobile phase A, 13%-17% mobile phase B; The mass spectrometer adopts ESI ion source and positive ion detection mode, wherein the quantitative ion of the methanesulfonic acid-2-pyridineethanol ester is: the parent ion is 202.3m / z, the daughter ion is 106.2m / z, and the collision voltage is 25V.
2. The method for detecting genotoxic impurities in betahistine mesylate according to claim 1, characterized in that: The elution procedure of the gradient elution is as follows: 0 min, 85% mobile phase A, 15% mobile phase B; 3 min, 85% mobile phase A, 15% mobile phase B; 5 min, 70% mobile phase A, 30% mobile phase B; 9 min, 5% mobile phase A, 95% mobile phase B; 10 min, 5% mobile phase A, 95% mobile phase B; 10.1 min, 85% mobile phase A, 15% mobile phase B; 15 min, 85% mobile phase A, 15% mobile phase B.
3. The method for detecting genotoxic impurities in betahistine mesylate according to any one of claims 1 to 2, characterized in that: The scanning mode of the mass spectrometer is multiple reaction monitoring, the curtain gas pressure is 40psi, the collision gas is Medium, the declustering voltage is 100V, the injection voltage is 5V-15V, the collision chamber emission voltage is 5V-15V, the ionization voltage is 5500V-4500V, the spray gas pressure is 50psi-60psi, the auxiliary heating gas pressure is 50psi-60psi, and the ionization temperature is 500℃-600℃.
4. The method for detecting genotoxic impurities in betahistine mesylate according to claim 1, characterized in that: The chromatographic column is YMC-Triart C18, 4.6mm*100mm, 3µm.
5. The method for detecting genotoxic impurities in betahistine mesylate according to claim 1, characterized in that: The column temperature was 27°C-33°C, and the flow rate was 0.55mL / min-0.65mL / min.
6. The method for detecting genotoxic impurities in betahistine mesylate according to claim 5, characterized in that: The column temperature was 30°C and the flow rate was 0.6 mL / min.
7. The method for detecting genotoxic impurities in betahistine mesylate according to claim 1, characterized in that: The injection volume was 1 µL.
8. The method for detecting genotoxic impurities in betahistine mesylate according to claim 1, characterized in that: The concentration of the test solution is 1 mg / mL.
9. The method for detecting genotoxic impurities in betahistine mesylate according to claim 1, characterized in that: The concentration of 2-pyridineethanol methanesulfonate in the reference solution is 40 ng / mL.
